The CCL2 ligand and its receptor CCR2 have been amply investigated in post-mortem and biopsy spinal cord/brain tissue samples from MS patients, ex vivo samples from EAE-affected animals, and in studies in vitro on specific cell lineages [18]. This evidence concerns the gene CCL2 and myeloid sarcoma.